| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5675617 | American Journal of Obstetrics and Gynecology | 2017 | 17 Pages |
Abstract
Our findings support that the Féderation Internationale de Gynécologie et d'Obstétrique s guidelines should include vascular space invasion and tumor size 2-4 cm and that careful selection of histologic type is essential for stratification of patient risk groups. High p53 levels independently predict poor survival yet do not reflect mutational status in cervical cancer. Amplified ERBB2 significantly links to poor survival, while HercepTest does not. With optimal stratification, human epidermal growth factor receptor 2-based therapy may improve cervical cancer treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Mari Kyllesø MSc, Akinyemi I. MD, PhD, Hilde MS, Kathrine MD, PhD, Ingvild Løberg PhD, Frederik PhD, Erling PhD, Kanthida PhD, Ingfrid S. MD, PhD, Olav K. MD, PhD, Jone MD, PhD, Bjørn I. MD, PhD, Helga B. MD, PhD, Camilla PhD,